Dr. Arno Bourgonje from University Medical Center Groningen, Netherlands, will present his most recent findings on "Personalized Redox Medicine in Inflammatory Bowel Disease”.
The discovery and validation of redox biomarkers for inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), need optimisation by prioritising central regulatory hubs, developing redox metabolomics approaches, and establishing integrative biomarkers that combine read-outs of multiple redox-regulated events. To make further progress, we should strive for personalized redox medicine, aiming for selective inhibition of pathologic overproduction or -expression of specific enzymatic sources of reactive species without affecting their physiological functions.
To this end, a finer understanding of disrupted redox signalling in IBD is required, together with renewed terminology and 'clinical -omics integration'. Pharmacological interventions activating endogenous antioxidant defense systems represent viable therapeutic options for restoring redox homeostasis.
Two main targets hold promise in the context of IBD: the hypoxia-inducible factor-1α (HIF1α) and the nuclear factor erythroid 2-derived factor 2 (NRF2). These redox-directed pharmacological interventions may offer new opportunities to break the therapeutic ceiling in IBD.
Join us in Paris Redox 2022 to listen to this brilliant talk and many more.
24th Annual ISANH Meeting
Paris Redox 2022 Congress
June 22-24, 2022 - Paris, France
www.isanh.net